Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study - PubMed
3 hours ago
- #clinical trial
- #HNSCC
- #amivantamab
- Amivantamab, an EGFR-MET bispecific antibody, showed an objective response rate (ORR) of 42% in recurrent/metastatic HNSCC patients after prior PD-(L)1 inhibitor and platinum-based chemotherapy.
- The study reported a median progression-free survival (PFS) of 6.8 months and median overall survival (OS) of 12.5 months, with a median follow-up of 11.8 months.
- Adverse events were consistent with prior amivantamab experience, with low treatment-related discontinuations at 8%, and no new safety signals identified.
- Amivantamab demonstrated superior antitumor activity compared to standard treatments like paclitaxel or cetuximab, which have ORRs of 21%-24% in similar patient populations.